Neighbors D. Pharmacoeconomic endpoints in FUMA3007: a randomized, open-label study comparing a 28-day oral regimen of 5-fluorouracil plus 776c85 to intravenous gemcitabine for the first-line treatment of patients with unresectable advanced adenocarcinoma of the pancreas. Presented at the Investigator Meeting; 1997. Atlanta, GA.